AnaptysBio Financial Statements (ANAB)
|
|
|
|
Report date
|
|
|
07.03.2022 |
01.03.2023 |
11.03.2024 |
27.02.2025 |
03.03.2026 |
|
03.03.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
63.2 |
10.3 |
17.2 |
91.3 |
234.6 |
|
234.6 |
|
Operating Income, bln rub |
|
|
-56.8 |
-115.2 |
-164.4 |
-114.9 |
47.9 |
|
47.9 |
|
EBITDA, bln rub |
? |
|
-55.7 |
-105.3 |
-156.4 |
-92.7 |
50.3 |
|
66.7 |
|
Net profit, bln rub |
? |
|
-57.8 |
-128.7 |
-163.6 |
-145.2 |
-13.2 |
|
-13.2 |
|
|
OCF, bln rub |
? |
|
-45.9 |
-73.6 |
-120.8 |
-135.3 |
19.7 |
|
19.7 |
|
CAPEX, bln rub |
? |
|
1.37 |
0.358 |
0.807 |
0.358 |
0.087 |
|
0.087 |
|
FCF, bln rub |
? |
|
-47.3 |
-74.0 |
-121.6 |
-135.7 |
19.6 |
|
19.6 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
21.5 |
36.6 |
49.3 |
42.4 |
184.3 |
|
184.3 |
|
Cost of production, bln rub |
|
|
98.5 |
88.8 |
132.3 |
163.8 |
2.42 |
|
218.4 |
|
R&D, bln rub |
|
|
98.5 |
88.8 |
139.6 |
163.8 |
136.0 |
|
136.0 |
|
Interest expenses, bln rub |
|
|
1.45 |
21.1 |
18.1 |
50.1 |
79.9 |
|
79.9 |
|
|
Assets, bln rub |
|
|
643.1 |
610.4 |
452.4 |
483.8 |
364.4 |
|
364.4 |
|
Net Assets, bln rub |
? |
|
356.4 |
262.1 |
88.1 |
70.9 |
37.2 |
|
37.2 |
|
Debt, bln rub |
|
|
21.0 |
19.5 |
17.8 |
369.5 |
14.1 |
|
290.6 |
|
Cash, bln rub |
|
|
548.1 |
441.2 |
390.9 |
385.4 |
311.6 |
|
311.6 |
|
Net debt, bln rub |
|
|
-527.1 |
-421.8 |
-373.1 |
-15.9 |
-297.5 |
|
-21.0 |
|
|
Ordinary share price, rub |
|
|
23.2 |
31.0 |
21.4 |
8.83 |
32.3 |
|
67.4 |
|
Number of ordinary shares, mln |
|
|
27.4 |
28.2 |
26.9 |
28.4 |
27.8 |
|
27.8 |
|
|
Market cap, bln rub |
|
|
636 |
873 |
577 |
251 |
898 |
|
1 872 |
|
EV, bln rub |
? |
|
108 |
451 |
204 |
235 |
601 |
|
1 851 |
|
Book value, bln rub |
|
|
356 |
262 |
88 |
71 |
37 |
|
37 |
|
|
EPS, rub |
? |
|
-2.11 |
-4.57 |
-6.08 |
-5.12 |
-0.48 |
|
-0.48 |
|
FCF/share, rub |
|
|
-1.72 |
-2.63 |
-4.52 |
-4.78 |
0.71 |
|
0.71 |
|
BV/share, rub |
|
|
13.0 |
9.31 |
3.27 |
2.50 |
1.34 |
|
1.34 |
|
|
EBITDA margin, % |
? |
|
-88.2% |
-1 023% |
-911.7% |
-101.6% |
21.4% |
|
28.4% |
|
Net margin, % |
? |
|
-91.5% |
-1 251% |
-953.7% |
-159.1% |
-5.64% |
|
-5.64% |
|
FCF yield, % |
? |
|
-7.44% |
-8.47% |
-21.1% |
-54.1% |
2.18% |
|
1.05% |
|
ROE, % |
? |
|
-16.2% |
-49.1% |
-185.7% |
-204.9% |
-35.6% |
|
-35.6% |
|
ROA, % |
? |
|
-8.99% |
-21.1% |
-36.2% |
-30.0% |
-3.63% |
|
-3.63% |
|
|
P/E |
? |
|
-11.0 |
-6.78 |
-3.52 |
-1.73 |
-67.9 |
|
-141.5 |
|
P/FCF |
|
|
-13.4 |
-11.8 |
-4.74 |
-1.85 |
45.8 |
|
95.5 |
|
P/S |
? |
|
10.1 |
84.8 |
33.6 |
2.75 |
3.83 |
|
7.98 |
|
P/BV |
? |
|
1.78 |
3.33 |
6.55 |
3.54 |
24.1 |
|
50.3 |
|
EV/EBITDA |
? |
|
-1.95 |
-4.29 |
-1.30 |
-2.53 |
11.9 |
|
27.7 |
|
Debt/EBITDA |
|
|
9.46 |
4.01 |
2.39 |
0.17 |
-5.91 |
|
-0.31 |
|
|
R&D/CAPEX, % |
|
|
7 211% |
24 804% |
17 301% |
45 765% |
156 287% |
|
156 287% |
|
|
CAPEX/Revenue, % |
|
|
2.16% |
3.48% |
4.70% |
0.39% |
0.04% |
|
0.04% |
|
| AnaptysBio shareholders |
